Literature DB >> 19492974

Predicting time to nursing home placement based on activities of daily living scores--a modelling analysis using data on Alzheimer's disease patients receiving rivastigmine or donepezil.

Hind T Hatoum1, Simu K Thomas, Swu-Jane Lin, Roger Lane, Roger Bullock.   

Abstract

OBJECTIVE: To quantify the impact of activities of daily living (ADL) scores on the risk of nursing home placement (NHP) in Alzheimer's disease (AD) patients.
SETTING: Models predicting NHP for AD patients have depended on cognitive deterioration as the primary measure. However, there is increased recognition that both patient functioning and cognition are predictive of disease progression.
METHODS: Using the database from a prospective, randomised, double-blind trial of rivastigmine and donepezil, two treatments indicated for AD, Cox regression models were constructed to predict the risk of NHP using age, gender, ADL and MMSE (Mini-Mental State Examination) scores as independent variables. PARTICIPANTS: Patients aged 50-85 years, with MMSE scores of 10-20, and a diagnosis of dementia of the Alzheimer type.
RESULTS: Cox regression analyses indicated that being female, older age, lower ADL score at baseline, and deterioration in ADL all significantly increased the risk of NHP. Over 2 years, risk of NHP increased by 3% for each 1-point deterioration in ADL score independent of cognition.
CONCLUSION: Data analyses from this long-term clinical trial established that daily functioning is an important predictor of time to NHP. Further research may be required to confirm whether this finding translates to the real world.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19492974     DOI: 10.3111/13696990903004039

Source DB:  PubMed          Journal:  J Med Econ        ISSN: 1369-6998            Impact factor:   2.448


  15 in total

1.  Risk Factors for Progression of Alzheimer Disease in a Canadian Population: The Canadian Outcomes Study in Dementia (COSID).

Authors:  Nathan Herrmann; Tetsuhiro Harimoto; Robert Balshaw; Krista L Lanctôt
Journal:  Can J Psychiatry       Date:  2015-04       Impact factor: 4.356

2.  OPTIMIZING DIAGNOSIS AND MANANGEMENT IN MILD-TO-MODERATE ALZHEIMER'S DISEASE.

Authors:  James E Galvin
Journal:  Neurodegener Dis Manag       Date:  2012-06

3.  Predictors of nursing home admission among Alzheimer's disease patients with psychosis and/or agitation.

Authors:  Edward Alan Miller; Lon S Schneider; Robert A Rosenheck
Journal:  Int Psychogeriatr       Date:  2010-03-10       Impact factor: 3.878

4.  Responder analysis of a randomized comparison of the 13.3 mg/24 h and 9.5 mg/24 h rivastigmine patch.

Authors:  José L Molinuevo; Lutz Frölich; George T Grossberg; James E Galvin; Jeffrey L Cummings; Tillmann Krahnke; Christine Strohmaier
Journal:  Alzheimers Res Ther       Date:  2015-03-08       Impact factor: 6.982

5.  Cholinesterase inhibitors do not alter the length of stay in nursing homes among patients with Alzheimer's disease: a prospective, observational study of factors affecting survival time from admission to death.

Authors:  Carina Wattmo; Elisabet Londos; Lennart Minthon
Journal:  BMC Neurol       Date:  2016-08-31       Impact factor: 2.474

6.  Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer's disease cohort.

Authors:  Carina Wattmo; Asa K Wallin; Lennart Minthon
Journal:  BMC Neurol       Date:  2012-11-05       Impact factor: 2.474

7.  A longitudinal study of risk factors for community-based home help services in Alzheimer's disease: the influence of cholinesterase inhibitor therapy.

Authors:  Carina Wattmo; Elisabeth Paulsson; Lennart Minthon; Elisabet Londos
Journal:  Clin Interv Aging       Date:  2013-03-20       Impact factor: 4.458

8.  Predictors of institutionalization of dementia patients in mild and moderate stages: a 4-year prospective analysis.

Authors:  Kathrin Eska; Elmar Graessel; Carolin Donath; Larissa Schwarzkopf; Joerg Lauterberg; Rolf Holle
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2013-11-01

9.  Solitary living in Alzheimer's disease over 3 years: association between cognitive and functional impairment and community-based services.

Authors:  Carina Wattmo; Elisabet Londos; Lennart Minthon
Journal:  Clin Interv Aging       Date:  2014-11-14       Impact factor: 4.458

Review 10.  A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer's disease.

Authors:  William James Deardorff; George T Grossberg
Journal:  Drug Des Devel Ther       Date:  2016-10-03       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.